In February 2024, the Multidistrict Litigation (MDL) had 74 pending Tepezza cases, all in early stages without scheduled trials or settlements yet approved by the court. These lawsuits stem from allegations that Horizon Therapeutics, the manufacturer of Tepezza, failed to adequately warn about health risks associated with the drug, leading to permanent hearing loss or tinnitus among users.
Key Updates:
- March 2023: Plaintiffs initiated a motion to consolidate cases into multidistrict litigation in the United States District Court for the Northern District of California.
- June 2023: Judges established an MDL in the Northern District of Illinois to centralize Tepezza cases under Judge Thomas M. Durkin.
Monthly Updates:
- August 2023: 46 Tepezza cases were pending in the MDL.
- July 2023: The newly formed MDL reported 42 pending cases.
- June 2023: Tepezza cases from across the country were consolidated into an MDL in Illinois.
- May 2023: The Panel on Multidistrict Litigation scheduled oral arguments regarding the consolidation motion.
- April 2023: Horizon filed a motion opposing the formation of an MDL in California.
- March 2023: Plaintiffs filed a motion to transfer and consolidate cases in California.
- October 2022: Horizon filed a motion to dismiss Weibel’s complaint.
- August 2022: Daniel Weibel filed one of the first Tepezza lawsuits in Illinois, alleging permanent hearing loss and tinnitus.
Case Background:
- In August 2022, Daniel Weibel filed one of the first Tepezza lawsuits in Illinois, alleging permanent hearing loss and tinnitus caused by the drug.
- Horizon opposed consolidating cases in California, preferring Illinois due to existing Tepezza lawsuits in the state.
- Ultimately, the MDL panel decided to transfer the cases to Illinois, where they will progress through discovery.
These updates mark ongoing developments in Tepezza litigation, as plaintiffs seek resolution for alleged injuries linked to the drug’s use.
